Actively Recruiting
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Led by Hospital Regional de Alta Especialidad del Bajio · Updated on 2025-03-12
20
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
H
Hospital Regional de Alta Especialidad del Bajio
Lead Sponsor
U
Universidad de Guanajuato
Collaborating Sponsor
AI-Summary
What this Trial Is About
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
CONDITIONS
Official Title
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Relapsed or refractory Hodgkin lymphoma after ABVD treatment with high-risk characteristics
- Age between 18 and 90 years
- Adequate liver function: total serum bilirubin ≤ 1.5 times the upper limit of normal, AST ≤ 3.0 times ULN, ALT ≤ 3.0 times ULN
- Adequate kidney function: serum creatinine ≤ 1.5 times ULN or glomerular filtration rate > 50 ml/min
- ECOG performance status of 3 or less
- Women of reproductive potential must have a negative serum or urine pregnancy test
- Signed informed consent prior to participation
You will not qualify if you...
- Voluntary withdrawal from the study
- Development of grade 3 or 4 toxicity according to the INH scale
- Loss of follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Regional Alta Especialidad Bajio
León, Guanajuato, Mexico, 37660
Actively Recruiting
Research Team
L
Lauro Fabián Amador, PhD
CONTACT
J
JUAN Ojeda Tovar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here